domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -37,16 +37,22 @@ MA plans' near-universal prior authorization creates administrative friction tha
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-16*
+*Source: 2025-05-01-nejm-semaglutide-mash-phase3-liver | Added: 2026-03-16*
 
 MASH/NASH is projected to become the leading cause of liver transplantation. GLP-1s now demonstrate efficacy across three major organ systems (cardiovascular, renal, hepatic), which strengthens the multi-indication economic case for chronic use. The 62.9% MASH resolution rate suggests GLP-1s could prevent progression to late-stage liver disease and transplantation, though the Value in Health Medicare study showed only $28M MASH savings—surprisingly small given clinical magnitude, likely because MASH progression to transplant takes decades and falls outside typical budget scoring windows.
 
 
 ### Additional Evidence (extend)
-*Source: [[2025-12-23-cms-balance-model-glp1-obesity-coverage]] | Added: 2026-03-16*
+*Source: 2025-12-23-cms-balance-model-glp1-obesity-coverage | Added: 2026-03-16*
 
 The BALANCE Model directly addresses the chronic use inflation problem by requiring lifestyle interventions alongside medication. If lifestyle supports can sustain metabolic benefits after medication discontinuation, the model could demonstrate a pathway to positive net cost impact. The 6-year test window (through 2031) will provide empirical data on whether combined intervention changes the chronic use economics.
 
+
+### Additional Evidence (challenge)
+*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
+
+The Trump Administration Medicare deal reduces GLP-1 prices to $245/month (82% below list) with narrow eligibility targeting high-comorbidity patients (BMI ≥27 with prediabetes/CVD or BMI >30 with heart failure/hypertension/CKD). The $50/month out-of-pocket cap removes financial barriers for eligible Medicare beneficiaries. This pricing + targeting combination may shift the cost-effectiveness calculus: if adherence improves due to affordability AND spending is concentrated on patients where multi-organ protection generates highest savings (kidney disease, heart failure, CVD), the 'inflationary through 2035' conclusion may not hold for the Medicare population under capitated payment models.
+
 ---
 
 Relevant Notes:

domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md

@@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained
 
 The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se.
 
+
+### Additional Evidence (confirm)
+*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16*
+
+The Medicare GLP-1 deal includes a $50/month out-of-pocket maximum for tirzepatide (Zepbound) starting April 2026, explicitly designed to address affordability as a discontinuation driver. The deal structure acknowledges that price, not just clinical factors, determines persistence—the policy intervention directly targets the affordability barrier identified in prior research.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "narrow-eligibility-targeting-in-public-drug-coverage-improves-cost-effectiveness-under-capitation-by-concentrating-spending-on-highest-savings-patients.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "manufacturer-price-concessions-in-exchange-for-coverage-expansion-creates-novel-policy-mechanism-bypassing-cms-rulemaking.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "narrow-eligibility-targeting-in-public-drug-coverage-improves-cost-effectiveness-under-capitation-by-concentrating-spending-on-highest-savings-patients.md:set_created:2026-03-16",
+      "manufacturer-price-concessions-in-exchange-for-coverage-expansion-creates-novel-policy-mechanism-bypassing-cms-rulemaking.md:set_created:2026-03-16"
+    ],
+    "rejections": [
+      "narrow-eligibility-targeting-in-public-drug-coverage-improves-cost-effectiveness-under-capitation-by-concentrating-spending-on-highest-savings-patients.md:missing_attribution_extractor",
+      "manufacturer-price-concessions-in-exchange-for-coverage-expansion-creates-novel-policy-mechanism-bypassing-cms-rulemaking.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-16"
+}

inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md

@@ -7,9 +7,13 @@ date: 2025-11-06
 domain: health
 secondary_domains: [internet-finance]
 format: news
-status: unprocessed
+status: enrichment
 priority: high
 tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure]
+processed_by: vida
+processed_date: 2026-03-16
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -45,3 +49,12 @@ On November 6, 2025, President Trump announced agreements with Eli Lilly and Nov
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: The price reduction + coverage expansion + narrow eligibility criteria fundamentally change the economics analyzed in the existing claim — the "inflationary through 2035" conclusion assumed higher prices and broader population
 EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) changes the cost-effectiveness calculus vs. broad population coverage
+
+
+## Key Facts
+- Medicare GLP-1 coverage demonstration begins July 2026
+- BALANCE Model in Medicaid launches May 2026
+- BALANCE Model in Medicare Part D launches January 2027
+- Oral Wegovy launching January 2026 at $149-$299/month
+- Approximately 10% of Medicare beneficiaries expected to be eligible under comorbidity criteria
+- $50/month out-of-pocket maximum for tirzepatide (Zepbound) for Medicare beneficiaries starting April 2026